Monday, February 13, 2017
Ariad v Lilly Appellants Brief and Follow On Biologics
Ariad v Lilly Appellants Brief and Follow On Biologics
Ariads brief in this important Federal Circuit en banc rehearing of Araid v. Lilly, which asks the court to consider revising or perhaps completely eliminating written description as a separate requirement of patentability is available here. I have not had a chance to read it yet, but will post some commentary once I do.
Also, for those interested in the follow-on biologics legislation currently being considered by Congress, here is a short version of the article I posted last week which focuses specifically on the patent provisions of the bills.
Available link for download
